Abstracts tagged "Autoinflammatory Disease and familial Mediterranean fever"

Abstract Number: 1319 • 2018 ACR/ARHP Annual Meeting
Familial Mediterranean Fever Related Damage Assessed By Auto-Inflammatory Disease Damage Index (ADDI) and Associated Factors with Damage
Abdurrahman Tufan¹, Berkan Armagan², Erdal Bodakci³, Timucin Kasifoglu⁴, Hasan Satis⁵, Nuh Atas¹, Alper Sari², Hakan Babaoglu¹, Gozde Yardımcı², Reyhan Salman¹, Levent Kilic², Nazife Sule Yasar Bilge³ and Mehmet Akif Ozturk¹, ¹Internal Medicine-Rheumatology, Gazi University Faculty of Medicine, Ankara, Turkey, ²Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Eskisehir Osmangazi University Faculty of Medicine, Eskişehir, Turkey, ⁵Rheumatology, Gazi University, Faculty of Medicine, Ankara, Turkey
Background/Purpose: Familial Mediterranean Fever (FMF) is the most frequent auto-inflammatory disease caused by MEFV gene mutations. Although FMF is characterized by intermittent inflammatory attacks some…
Abstract Number: 1174 • 2017 ACR/ARHP Annual Meeting
Which Definition Should be Used to Determine Colchicine Resistance in Patients with Familial Mediterranean Fever?
Abdulsamet Erden¹, Ezgi Deniz Batu², Alper Sari³, Hafize Emine Sonmez⁴, Berkan Armagan³, Selcan Demir⁴, Esra Fırat⁵, Yelda Bilginer⁶, Sule Apras Bilgen¹, Omer Karadag¹, Umut Kalyoncu¹, Sedat Kiraz¹, Ihsan Ertenli¹, Seza Ozen⁷ and Ali Akdogan³, ¹Department of Internal Medicine, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Department of Pediatrics, Divison of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ³Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁴Department of Pediatrics, Divison of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁵Department of Internal Medicine, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁶Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ⁷Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Colchicine is the main therapy for familial Mediterranean fever (FMF); however, around 5-10% of FMF patients are colchicine-resistant. Currently there is no standard and…
Abstract Number: 2113 • 2017 ACR/ARHP Annual Meeting
Familial Mediterranean Fever in Chinese Adult Patients
Di Wu and Min Shen, Rheumatology, Peking Union Medical College Hospital, Beijing, China
Background/Purpose :Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease (AUID) worldwide. There have been hardly any cases reported in Chinese population. We…
Abstract Number: 79 • 2016 ACR/ARHP Annual Meeting
A NOVEL Missense Mvk mutation in a Family with Familial Mediterranean Fever-like Disease
Ilker Karacan¹, Serdal Ugurlu², Aslihan Tolun³, Eda Tahir Turanli¹ and Huri Ozdogan², ¹Department of Molecular Biology and Genetics, İstanbul Technical University, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Department of Molecular Biology and Genetics, Boğaziçi University, Istanbu, Turkey
Background/Purpose: Monogenic autoinflammatory diseases are mainly disorders of innate immunity and characterized by unprovoked inflammatory attacks. We studied a consanguineous family with two affected children,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].